Ignite Creation Date:
2025-12-24 @ 12:31 PM
Ignite Modification Date:
2026-02-08 @ 3:45 PM
Study NCT ID:
NCT05940961
Status:
RECRUITING
Last Update Posted:
2025-11-21
First Post:
2023-07-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
Sponsor:
Sheng-Li Xue, MD
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
szINO
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None